X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to manufacture and advance BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease, and BBP-631, an investigational AAV 5 gene therapy for congenital adrenal hyperplasia (CAH).
Lead Product(s): BBP-812
Therapeutic Area: Genetic Disease Product Name: BBP-812
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BridgeBio Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 03, 2023
Details:
The focus will be on therapies derived from biologics — cells, blood, enzymes, tissues, genes, or genetically engineered cells — for use in medicines. In addition, the collaboration seeks to advance biologic discoveries toward early stage clinical trials.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 15, 2022
Details:
Resilience will provide process development and GMP manufacturing services including cell lines and viral banks for AavantiBio’s AVV-based therapeutic FA candidate for use in both pre-clinical studies, and Phase I/II trials in the U.S. and Europe.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AavantiBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
